Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells

BMC Pulmonary Medicine

Volumn 12, Issue , 2012, Pages

  Hisatomi, Keiko ^a   Mukae, Hiroshi ^b   Sakamoto, Noriho ^a   Ishimatsu, Yuji ^a   Kakugawa, Tomoyuki ^a   Hara, Shintaro ^a   Fujita, Hanako ^a   Nakamichi, Seiko ^c   Oku, Hisashi ^d   Urata, Yoshishige ^e   Kubota, Hiroshi ^f   Nagata, Kazuhiro ^f   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Epithelial cell; Epithelial mesenchymal transition; Interstitial pneumonia; Pneumocyte; Pulmonary fibrosis

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; HEAT SHOCK PROTEIN 47; MESSENGER RNA; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; CADHERIN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ARTICLE; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; NORTHERN BLOTTING; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE EXPRESSION; GENETICS; LUNG; LUNG FIBROSIS; METABOLISM; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CADHERINS; CELL LINE; COLLAGEN TYPE I; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION; HSP47 HEAT-SHOCK PROTEINS; HUMANS; LUNG; PULMONARY FIBROSIS; PYRIDONES; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84862201665     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-12-24     Document Type: Article

References (33)

1. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168(5):543-548. 10.1164/rccm.200209-1112OC, 12773329.
2. Willis BC, DuBois RM, Borok Z. Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 2006, 3(4)):377-382. 2658689, 16738204.
3. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005, 6:56. 10.1186/1465-9921-6-56, 1177991, 15946381.
4. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006, 103(35):13180-13185. 10.1073/pnas.0605669103, 1551904, 16924102.
5. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005, 166(5):1321-1332. 10.1016/S0002-9440(10)62351-6, 1606388, 15855634.
6. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006, 3(4):364-372. 10.1513/pats.200601-003TK, 16738202.
7. Di Sario A, Bendia E, Macarri G, Candelaresi C, Taffetani S, Marzioni M, Omenetti A, De Minicis S, Trozzi L, Benedetti A. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 2004, 36(11):744-751. 10.1016/j.dld.2004.05.012, 15571005.
8. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, Becker GJ. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001, 14(6):453-460.
9. Iyer SN, Margolin SB, Hyde DM, Giri SN. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model. Exp Lung Res 1998, 24(1):119-132. 10.3109/01902149809046058, 9457473.
10. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999, 291(1):367-373.
11. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000, 24(5):477-491. 10.1023/A:1007068313370, 10921510.
12. Kakugawa T, Mukae H, Hayashi T, Ishii H, Abe K, Fujii T, Oku H, Miyazaki M, Kadota J, Kohno S. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004, 24(1):57-65. 10.1183/09031936.04.00120803, 15293605.
13. Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett 1997, 90(2-3):125-132.
14. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999, 276(2 Pt 1):L311-L318.
15. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002, 446(1-3):177-185.
16. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002, 446(1-3):167-176.
17. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med 1999, 159(4 Pt 1):1061-1069.
18. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171(9):1040-1047. 10.1164/rccm.200404-571OC, 15665326.
19. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35(4):821-829. 10.1183/09031936.00005209, 19996196.
20. Nakayama S, Mukae H, Sakamoto N, Kakugawa T, Yoshioka S, Soda H, Oku H, Urata Y, Kondo T, Kubota H, et al. Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. Life Sci 2008, 82(3-4):210-217.
21. Ishida Y, Kubota H, Yamamoto A, Kitamura A, Bachinger HP, Nagata K. Type I collagen in Hsp47-null cells is aggregated in endoplasmic reticulum and deficient in N-propeptide processing and fibrillogenesis. Mol Biol Cell 2006, 17(5):2346-2355. 10.1091/mbc.E05-11-1065, 1446091, 16525016.
22. Saga S, Nagata K, Chen WT, Yamada KM. pH-dependent function, purification, and intracellular location of a major collagen-binding glycoprotein. J Cell Biol 1987, 105(1):517-527. 10.1083/jcb.105.1.517, 2114926, 3038929.
23. Sauk JJ, Smith T, Norris K, Ferreira L. Hsp47 and the translation-translocation machinery cooperate in the production of alpha 1(I) chains of type I procollagen. J Biol Chem 1994, 269(6):3941-3946.
24. Abe K, Ozono Y, Miyazaki M, Koji T, Shioshita K, Furusu A, Tsukasaki S, Matsuya F, Hosokawa N, Harada T, et al. Interstitial expression of heat shock protein 47 and alpha-smooth muscle actin in renal allograft failure. Nephrol Dial Transplant 2000, 15(4):529-535. 10.1093/ndt/15.4.529, 10727549.
25. Shioshita K, Miyazaki M, Ozono Y, Abe K, Taura K, Harada T, Koji T, Taguchi T, Kohno S. Expression of heat shock proteins 47 and 70 in the peritoneum of patients on continuous ambulatory peritoneal dialysis. Kidney Int 2000, 57(2):619-631. 10.1046/j.1523-1755.2000.00883.x, 10652040.
26. Kakugawa T, Mukae H, Hayashi T, Ishii H, Nakayama S, Sakamoto N, Yoshioka S, Sugiyama K, Mine M, Mizuta Y, et al. Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia. Respir Res 2005, 6:57. 10.1186/1465-9921-6-57, 1200429, 15955241.
27. Ishii H, Mukae H, Kakugawa T, Iwashita T, Kaida H, Fujii T, Hayashi T, Kadota J, Kohno S. Increased expression of collagen-binding heat shock protein 47 in murine bleomycin-induced pneumopathy. Am J Physiol Lung Cell Mol Physiol 2003, 285(4):L957-L963.
28. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119(6):1429-1437. 10.1172/JCI36183, 2689132, 19487819.
29. Yoshioka S, Mukae H, Ishii H, Kakugawa T, Ishimoto H, Sakamoto N, Fujii T, Urata Y, Kondo T, Kubota H, et al. Alpha-defensin enhances expression of HSP47 and collagen-1 in human lung fibroblasts. Life Sci 2007, 80(20):1839-1845. 10.1016/j.lfs.2007.02.014, 17367817.
30. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, Colby TV. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175(7):705-711. 10.1164/rccm.200607-912OC, 17218621.
31. Sunamoto M, Kuze K, Tsuji H, Ohishi N, Yagi K, Nagata K, Kita T, Doi T. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress collagen accumulation in experimental glomerulonephritis. Lab Invest 1998, 78(8):967-972.
32. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, Ozono Y, Koji T, Kohno S. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003, 64(3):887-896. 10.1046/j.1523-1755.2003.00169.x, 12911538.
33. Yao HW, Xie QM, Chen JQ, Deng YM, Tang HF. TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. Life Sci 2004, 76(1):29-37. 10.1016/j.lfs.2004.06.019, 15501477.